STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] CYBIN INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Cybin Inc. (CYBN) received a Schedule 13G showing that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively report beneficial ownership of 3,072,250 common shares, representing 6.09% of the class as of the reported date.

The filing lists shared voting and dispositive power over 3,072,250 shares and no sole voting or dispositive power. The ownership calculation references 50,431,381 shares, derived from 49,894,131 shares outstanding as of October 28, 2025 plus 537,250 warrants that are exercisable subject to a 9.99% Maximum Percentage beneficial ownership cap. The certification states the securities were not acquired to change or influence control.

Positive
  • None.
Negative
  • None.

Insights

Routine 13G discloses a 6.09% passive stake in CYBN.

The report identifies Deep Track Capital, its biotech master fund, and David Kroin as reporting persons with 6.09% beneficial ownership, totaling 3,072,250 common shares. Voting and dispositive powers are shared, with no sole power indicated, consistent with a coordinated investment structure.

The share count is based on 49,894,131 shares outstanding as of Oct 28, 2025 plus 537,250 warrants counted within the 9.99% Maximum Percentage limit. The certification states the position is not held to influence control, aligning this with a passive 13G filing.

The mechanics of any future changes depend on holder actions and warrant constraints disclosed; the filing itself does not specify timing for transactions.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Deep Track Capital, LP
Signature:/s/ David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:11/04/2025
Deep Track Biotechnology Master Fund, Ltd.
Signature:/s/ David Kroin
Name/Title:David Kroin, Director
Date:11/04/2025
David Kroin
Signature:/s/ David Kroin
Name/Title:David Kroin
Date:11/04/2025
Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of November 4, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 50,431,381 shares, calculated using 49,894,131 Common Stock outstanding as of October 28, 2025, and 537,250 Warrants that would be converted to Common Stock by the Reporting Person up to the Maximum Percentage. The beneficially owned shares include 537,250 Warrants exercisable to common stock, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of the Warrants, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Common Stock outstanding immediately after giving effect to such exercise. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 4, 2025 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

FAQ

What ownership stake in Cybin (CYBN) is reported?

The filing reports 6.09% beneficial ownership, or 3,072,250 common shares.

Who are the reporting persons in this Schedule 13G for CYBN?

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin.

How is voting and dispositive power allocated?

The reporting persons have shared voting power over 3,072,250 shares and shared dispositive power over 3,072,250 shares; no sole power.

What baseline share count was used for the percentage calculation?

It references 50,431,381 shares, based on 49,894,131 shares outstanding as of October 28, 2025 plus 537,250 warrants.

What is the 9.99% Maximum Percentage referenced?

It is a beneficial ownership cap of 9.99% limiting warrant exercises so ownership does not exceed that threshold.

Are the securities held to influence control of Cybin?

The certification states they were not acquired and are not held to change or influence control.

What is the date of the event requiring this filing?

The date of event is October 28, 2025.
Cybin Inc

NYSE:CYBN

CYBN Rankings

CYBN Latest News

CYBN Latest SEC Filings

CYBN Stock Data

296.93M
18.77M
98.65%
38.53%
10.87%
Biotechnology
Healthcare
Link
Canada
Toronto